Molecular Partners

Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024

Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects MP0621 presently in IND-enabling studies with phase 1 in AML anticipated in 2025. 14 June 2024 --...
Wagistrasse 14 8952 Zurich-Schlieren Switzerland

+41 44 755 77 00